Ropinirole transdermal - Hisamitsu

Drug Profile

Ropinirole transdermal - Hisamitsu

Alternative Names: HP 3000

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease
  • Phase II Restless legs syndrome

Most Recent Events

  • 16 Nov 2017 Hisamitsu Pharmaceutical completes a phase III trial in Parkinson's disease (In adults, In the elderly) in Japan (Transdermal) (JapicCTI142748)
  • 05 Sep 2017 Ropinirole transdermal is still in phase III trials for Parkinson's disease (In adults, In the elderly) in Japan (Transdermal) (JapicCTI-152870) (JapicCTI-142748)
  • 07 Jul 2017 Ropinirole transdermal is still under phase II development for Restless legs syndrome in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top